Cl-NQTrp

Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein. In Vitro Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils. Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau. Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elav c155 -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control. Dosage: 0.75 mg/mL. Administration: Dripped every other day. Result: Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau). Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet